1. Clinical actionability and therapy selection for advanced NSCLC patients tested using comprehensive genomic profiling. (October 2022) Authors: Bapat, B.; Weerasinghe, R.; Meng, R.; Dowdell, A.; Chang, S.C.; Schroeder, B.; Bifulco, C.; Piening, B. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α. (June 2017) Authors: Berinstein, N.; Smyth, L.; Pennell, N.; Weerasinghe, R.; Cheung, M.; Imrie, K.; Spaner, D.; Chodirker, L.; Piliotis, E.; Milliken, V.; Boudreau, A.; Zhang, L.; Reis, M.; Chesney, A.; Good, D.; Ghorab, Z.; Buckstein, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0219 PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND RESOURCE UTILIZATION OF SJOGREN'S SYNDROME PATIENTS IN A LARGE US HEALTH NETWORK. (2nd June 2020) Authors: Mease, P. J.; Zhuo, J.; Weerasinghe, R.; Xia, Q.; Samal, C.; Sharma, N. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗